FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
November 24, 2015
Sales efforts will address access to ECG screening through pharmacies and primary care physician offices in Eastern Canada
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical and consumer provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced it has engaged Nu-Quest Distribution Inc. (“Nu-Quest”), located in Mount Pearl, Newfoundland as its Eastern Canada medical technology distributor.
Nu-Quest will be responsible for development and management of sales and distribution channels for the sale of CardioComm Solutions’ HeartCheck™ ECG technologies as well as the Company’s ECG management software known as the Global ECG Management System for Windows (GEMS™ WIN) through hospitals, clinics and health care providers within Newfoundland and Labrador.
Nu-Quest Distribution Inc. is a Newfoundland and Labrador family owned and operated pharmaceutical wholesaler that was founded in 1996, whose motto is “Putting your customers first”. Nu-Quest distributes Canadian Federally approved medications, medical equipment, supplies and accessories serving pharmacies, physicians, hospitals, clinics and veterinarians. They are a registered member of the Canadian Association for Pharmacy Distribution Management (CAPDM).
A Nu-Quest representative commented that, “Nu-Quest serves approximately 150 local pharmacies and a number of physician offices. Newfoundland is a unique province geographically and for most living there, hospitals and clinics are miles away. The HeartCheck™ ECG monitor would provide an added value to patients of the province who have heart conditions by allowing them to be able to monitor their heart rhythm and ECG without having to leave the comfort of their own home. We are pleased to introduce the HearthCheck™ ECG PEN to our portfolio and providing access to patients is our main goal”.
CardioComm Solutions is intent on providing cutting edge technology for use in locations where large urban or university based hospitals and tertiary centers are less available. Through the Company’s HeartCheck™, SMART Monitoring ECG Service, GEMS™ WIN and the recently announced GEMS™ Home Rx for physician use, CardioComm Solutions will provide access to their cardiology-based GEMS™ software for the remote monitoring of patients and consumers for extended periods of time while outside the environment of a hospital or physician’s office and while and engaged in their daily lives.
This is the fourth strategic partnership reported by CardioComm Solutions since July and the Company has stated that more will be announced as sales from new distributors are confirmed. To learn more about the CardioComm Solutions products and devices compatible with GEMS™ WIN please see the Company’s website www.cardiocommsolutions.com or contact the Company at firstname.lastname@example.org.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.